The expression of sirtuins in breast cancer and their prognostic and clinicopathological significance: a systematic review

Ehsan  Naseri; Zohreh  Abdolvahabi; Banafsheh  Safizadeh; Hannaneh  Zarrinnahad; Yousef  Moradi; Marzieh  Soheili; Hamid Reza  Baradaran; Mitra  Nourbakhsh

doi:10.18502/abi.v2i2.17932

Ehsan Naseri Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Zohreh Abdolvahabi Non-communicable Diseases Research Center, Research Institute for Prevention of Non-communicable diseases, Qazvin University of Medical Sciences, Qazvin, Iran
Banafsheh Safizadeh Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Ira
Hannaneh Zarrinnahad Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Ira
Yousef Moradi Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
Marzieh Soheili College of Pharmacy, Western New England University, Springfield, MA, United States
Hamid Reza Baradaran Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
Mitra Nourbakhsh Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/abi.v2i2.17932

Keywords: Sirtuins, Breast Cancer, SIRTs, clinicopathological, survival, prognostic

Abstract

Objectives: Sirtuins (SIRTs) are a highly conserved family of enzymes that play an important role in cancer emergence and progression, including breast cancer. In this review, changes in the expression of different SIRTs in breast cancer and their association with metastasis and cancer grade were investigated.

Methods: This study was performed on 44 selected articles on breast cancer, which were extracted from PubMed, Scopus, and Web of Science. Among the selected articles, there were 31 case-control and 13 cohort studies with a total of 7326 and 4760 participants, respectively.

Results: In most studies, SIRT1, SIRT5, and SIRT7 expression levels were higher than the controls, while the expression levels of SIRT4 and SIRT6 were lower. Elevated levels of SIRT1 were associated with an increased risk of distant metastatic relapse (DMR), death, and recurrence, as well as reduced relapse-free survival (RFS). Additionally, there was a significant correlation between increased levels of SIRT1 and metastasis of lymph nodes and other tissues. Reduced levels of SIRT4 were associated with decreased overall survival (OS).

Conclusion: Our findings suggest that elevated levels of SIRT1, SIRT5, and SIRT7 may have potential value for use in the diagnosis of breast cancer. Increased levels of SIRT1 can be used as a prognostic marker.